Organization | Clinical Evaluation Research Unit at Kingston General Hospital

Clinical Evaluation Research Unit at Kingston General Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2010

NCT00934934

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Daren K. Heyland

Active Ingredients

Drugs in Phase 3 Trials (2)

l-glutamine (1 trial)

sodium selenium oxide (1 trial)

Drugs in Phase 2 Trials (2)

anidulafungin (eraxis) (1 trial)

sodium chloride (1 trial)

Drugs in Other Trials (5)

dopamine (intropin) (1 trial)

epinephrine (levophed) (1 trial)

norepinephrine (levophed) (1 trial)

phenylephrine (Prefrin) (1 trial)

vasopressin (vasostrict) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Heart Diseases (Phase 3)

Pneumonia (Phase 2)

Pneumonia, Ventilator-Associated (Phase 2)

Respiratory Tract Infections (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 9